Newsroom

Veradermics Doses First Patient in Phase 2 Clinical Trial for VDMN for the Treatment of Common Warts

Veradermics Inc. Secures Licensing of First-in-Class Antiviral Targeting the Treatment of Molluscum Contagiosum and other Poxviruses